Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Withdrawn × Ear Neoplasms × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 50 Breast Neoplasms 47 Carcinoma, Non-Small-Cell Lung 38 Leukemia, Myeloid, Acute 35 Lymphoma 32 Pancreatic Neoplasms 29 Leukemia 27 Leukemia, Lymphocytic, Chronic, B-Cell 26 Precursor Cell Lymphoblastic Leukemia-Lymphoma 24 Ovarian Neoplasms 24 Lymphoma, Non-Hodgkin 24 Multiple Myeloma 23 Neoplasm Metastasis 21 Lung Neoplasms 21 Recurrence 20 Lymphoma, Large B-Cell, Diffuse 20 Glioblastoma 20 Brain Neoplasms 19 Prostatic Neoplasms 18 Melanoma 18 Lymphoma, Follicular 16 Colorectal Neoplasms 16 Squamous Cell Carcinoma of Head and Neck 14 Sarcoma 13 Lymphoma, Mantle-Cell 13 Lymphoma, B-Cell 13 Urinary Bladder Neoplasms 12 Lymphoma, B-Cell, Marginal Zone 11 Hematologic Neoplasms 11 Glioma 11

Interventions

Saline Solution 1 Ringer's Lactate 1 Ofloxacin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00584155 2015-05-27

Protection From Cisplatin Ototoxicity by Lactated Ringers

University of Oklahoma

Phase 1 Withdrawn

Ear Neoplasms, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon ⚡